Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

TriSalus Life Sciences, Inc. (TLSI) had Revenue of $9.17M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$9.17M
Net Income	$-11.09M
Cost of Goods Sold	$1.50M
Gross Profit	$7.67M
Operating Expenses	$16.50M
Operating Income	$-7.33M
Non-Operating Income/Expense	$-3.04M
Pre-Tax Income	$-10.37M
Normalized Pre-Tax Income	$-10.37M
Income after Taxes	$-10.37M
Income from Continuous Operations	$-10.37M
Consolidated Net Income/Loss	$-10.38M
Normalized Income after Taxes	$-10.37M
EBIT	$-7.33M
EBITDA	$-6.92M
Weighted-Average Shares Outstanding (Basic)	28.53M
Weighted-Average Shares Outstanding (Diluted)	28.53M
Earnings per Share (EPS) (Basic)	$-0.39
Earnings per Share (EPS) (Diluted)	$-0.39
Balance Sheet Financials
Current Assets	$25.10M
Property, Plant, and Equipment	$1.97M
Long-Term Assets	$3.53M
Total Assets	$28.62M
Current Liabilities	$11.75M
Long-Term Debt	$31.70M
Long-Term Liabilities	$51.24M
Total Liabilities	$62.99M
Common Equity	$-34.37M
Tangible Shareholders Equity	$-34.37M
Shareholders Equity	$-34.37M
Common Shares Outstanding	32.27M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-4.50M
Cash Flow from Investing Activities	$-0.71M
Cash Flow from Financial Activities	$9.69M
Beginning Cash	$8.88M
End Cash	$13.35M
Increase/Decrease in Cash	$4.47M
Stock-Based Compensation	$1.62M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.14
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-11.87
Debt to Equity Ratio	-0.92
Gross Margin	83.69%
Operating Margin	-79.95%
EBIT Margin	-79.95%
EBITDA Margin	--
Pre-Tax Profit Margin	-113.12%
Profit Margin	-120.94%
Free Cash Flow	$-5.21M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.32
Inventory Turnover	0.36
Receiveable Turnover	1.68
Days Sales in Receivables	53.54
Return on Equity	30.16%
Return on Tangible Equity	30.16%
Return on Assets	-36.21%
Return on Investments	388.06%
Book Value Per Share	$-1.06
Free Cash Flow per Share	$-0.18
Operating Cash Flow per Share	$-0.16

Data from Zacks Investment Research, Inc.